The global Erythropoietin Drugs market size is expected to be worth around US$ 27.4 billion by 2030, according to a new report by Vision Research Reports.
The global Erythropoietin Drugs market size was valued at US$ 17.4 billion in 2020 and is anticipated to grow at a CAGR of 21.5% during forecast period 2021 to 2030.
Growth Factors
Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market.
According to the statistics published by the National Heart, Lung, and Blood Institute of the U.S. Department of Health & Human Services, over 3 million people are affected by anemia every year and this number is expected to increase over the forecast period. This showcases the need for erythropoietin-stimulating agents in the coming years.
Introduction of novel drugs and their cheaper biosimilar formulations with enhanced efficacy and cost-effectiveness is also expected to serve this industry with lucrative opportunities. For instance, development of numerous in the European market is expected to gain traction and increase their usage rates, owing to associated benefits such as less time required for approval, cost-efficiency, and enhanced therapeutic effect.
Companies are involved in extensive R&D initiatives for development of innovative molecules and discovering new therapeutic areas for existing drugs. For instance, in April 2016, Sandoz received approval from the European Commission for use of its biosimilar Binocrit in nephrology indications, thereby extending the therapeutic area of its product portfolio.
Report Highlights
Of the various drug classes, the biologics erythropoietin class held a dominant share as of 2020, owing to patent protection. Presence of large patient population and higher uptake of biologics are other contributing factors towards its dominance. In addition, the availability of very few biologics in the market has led to increased adoption. Furthermore, owing to its wide applications in the treatment of CKD, the biologics segment accounted for the majority of the revenue share.
The biologics segment is anticipated to lose its market share due to recent patent expiration of major brands such as Epogen. This drug lost its patent exclusivity in May 2015, which resulted in reduced sales revenue for its manufacturer company, Amgen Inc.
Biosimilars are expected to gain popularity in the near future for the treatment of anemic conditions. Biosimilars are easy to develop, cost-effective, and require less time for approval as compared to biologics. These associated advantages are expected to propel the segment growth throughout the forecast period.
Increasing investments in R&D for biosimilars, strong product pipeline, and collaborations between hospitals &manufactures for the adoption of EPO biosimilars are key market drivers for the growth of the biosimilar segment. The recent launch of erythropoietin biosimilars in the U.S. is further expected to showcase a paradigm shift in global EPO drugs from biologics to biosimilars.
In the product segment, Epoetin-alfa held a dominant share due to its wide adoption amongst healthcare professionals. This product was the first biologic to be approved by the U.S.FDA for the treatment of anemia resulting from CKD, cancer chemotherapy, and HIV treatment. Epoetin-alfa was patent-protected, which restricted the production of any other recombinant human erythropoietin drug and helped this segment dominate in 2020.
Epoetin-beta is a recombinant form of epoetin-alfa. This segment held a considerable share in the products segment owing to its benefits such as improved efficacy and a longer half-life in comparison with epoetin-alfa. NeoRecormon, developed by F. Hoffman-La Roche, is the first drug containing epoetin-beta as the active ingredient.
Darbepoetin-alfa is yet another novel erythropoietin drug developed by Amgen, Inc., which is marketed under the brand name Aranesp. The patent for this drug expires in 2024 in the U.S. Until this period, this drug enjoys patent exclusivity rights in the U.S. In Europe, the patent for Aranesp expired in 2020, due to which the sales of this drug have decreased in this region.
Darbepoetin-alfa is anticipated to witness positive growth in the future due to its cost-effectiveness, improved efficacy, and longer half-life. This is a viable solution for the treatment of anemia rising from end-stage renal diseases. Research is being undertaken for the discovery of new therapeutic areas for the application of darbepoetin-alfa, which is expected to serve this industry with growth potential.
Other medications such as epoetin-zeta and epoetin-omega are expected to exhibit a lucrative growth rate in the coming years. These are biosimilar formulations of epoetin-alfa but are more effective in the treatment of anemic conditions. EporatiobyTeva Pharmaceutical Industries, Ltd. and Mircera by F. Hoffmann-La Roche Ltd. are major products in this segment.
Renal diseases held a dominant share as prevalence of anemia is increasing at a constant rate. The first erythropoietin drug, Epogen was approved by the U.S. FDA for the treatment of anemic indications arising from CKD. Owing to early introduction of this drug for the treatment of CKD and rising incidence of the same, this segment dominated as of 2020.
The cancer segment is expected to be the fastest-growing segment owing to the increasing number of cancer incidence worldwide. Cancer chemotherapy involves the use of medication that reduces the RBC count amongst patients. As a result, usage of these alongside chemotherapy has become common in recent years. This has resulted in increasing demand for EPO drugs for cancer treatment, which augments growth.
The hematology segment is anticipated to witness steady growth over the forecast period due to rising R&D initiatives to develop cost-effective and viable solutions for treating conditions such as hypoxia and anemia of prematurity. Proper dosage of recombinant human erythropoietin can cure anemia of prematurity and reduces the need of multiple blood transfusion in neonates. This is expected to serve this industry with growth potential.
The neurology segment is expected to showcase growth over the forecast period as many of the erythropoietin drugs are considered to be an effective solution for treating neurological disorders such as Parkinson’s disease. Companies are involved in discovering new therapeutic areas for application of erythropoietin-stimulating agents, apart from the treatment of anemia. Major therapeutic research is being carried out for the neurology segment.
North America held a considerable share of erythropoietin drugs as of 2020 owing to increasing incidence of chronic diseases such as cancer, CKD, and HIV. According to the Centers for Disease Control and Prevention (CDC), 1.2 million people in the U.S. are living with HIV and 39,513 cases were diagnosed in 2015. These statistics indicate the need for EPO drugs over the forecast period.
In order to satisfy unmet needs, favorable reimbursement policies for HIV treatment are developed by the U.S. government. This would in turn provide a healthy platform for the growth of the North American EPO market. Furthermore, owing to the patent expiration of biologics, numerous new players have entered the market in this region and are undertaking various strategic steps to gain more revenue share. For instance, in October 2020, Teva Pharmaceutical Industries Ltd. acquired Anda, Inc., a leading distributor of generics in the U.S. from Allergan, plc., thereby strengthening its distribution network.
The Asia Pacific EPO industry is anticipated to grow at the fastest CAGR due to continuous rise in the incidence of chronic diseases coupled with high demand for low-cost therapeutics. Asia Pacific has attracted significant interest in many companies for the development of biosimilars and is known for developing more biosimilars, than anywhere else in the globe.
Moreover, increasing government initiatives to provide better health amenities to public in this region is another contributing factor for market growth. For instance, the Japanese government has passed a regulation to price biosimilars at a discount of 30% in comparison to making it available to people belonging to lower economic class at subsidized prices.
Key Players
Johnson & Johnson; Celltrion, Inc.; Teva Pharmaceutical Industries Ltd.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; LG Life Sciences Ltd.; Biocon Limited; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.; and Dr. Reddy’s Laboratories Ltd.
Market Segmentation
Drug Class Outlook
Biologics
Biosimilars
Product Outlook
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Application Outlook
Cancer
Hematology
Renal diseases
Neurology
Regional Outlook
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
The Middle East and Africa
South Africa
The Erythropoietin Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Erythropoietin Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Erythropoietin Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Erythropoietin Drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Erythropoietin Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Erythropoietin Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Erythropoietin Drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Erythropoietin Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Erythropoietin Drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Erythropoietin Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Erythropoietin Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Erythropoietin Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Erythropoietin Drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Erythropoietin Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Erythropoietin Drugs market. These factors have benefited the growth of the global market for Erythropoietin Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Erythropoietin Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Erythropoietin Drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers